Novelix Pharmaceuticals Limited (BOM:536565)
India
· Delayed Price · Currency is INR 53.90
+0.80 (1.51%)
At close: Mar 10, 2026
Novelix Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,280 | 307.18 | 42.24 | 14.05 | 86.09 | 92.42 | Upgrade
|
| Other Revenue | 0.32 | 0.15 | 3.07 | 5.16 | 3.04 | 3.43 | Upgrade
|
| Revenue | 1,280 | 307.33 | 45.31 | 19.2 | 89.13 | 95.85 | Upgrade
|
| Revenue Growth (YoY) | 1084.24% | 578.26% | 135.96% | -78.45% | -7.01% | -11.60% | Upgrade
|
| Cost of Revenue | 1,241 | 295.86 | 38.45 | 13.83 | 82.94 | 85.61 | Upgrade
|
| Gross Profit | 38.93 | 11.47 | 6.86 | 5.38 | 6.18 | 10.24 | Upgrade
|
| Selling, General & Admin | 5.07 | 0.89 | 1.88 | 3.56 | 5.79 | 9.91 | Upgrade
|
| Other Operating Expenses | 9.22 | 8.93 | 2.84 | 1.84 | 3.61 | 34.85 | Upgrade
|
| Operating Expenses | 15.08 | 10.21 | 6.48 | 5.96 | 11 | 46.85 | Upgrade
|
| Operating Income | 23.85 | 1.27 | 0.38 | -0.58 | -4.82 | -36.61 | Upgrade
|
| Interest Expense | - | - | - | - | -0.58 | -0.54 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | - | - | - | - | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 0.87 | -0.23 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0 | 0 | 0 | - | -0.13 | Upgrade
|
| EBT Excluding Unusual Items | 23.86 | 1.28 | 0.38 | -0.58 | -4.53 | -37.51 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -15.6 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.04 | -0.04 | -0.17 | - | -0.23 | - | Upgrade
|
| Pretax Income | 23.82 | 1.23 | 0.21 | -0.58 | -20.35 | -37.51 | Upgrade
|
| Income Tax Expense | 5.76 | 0.39 | 0.11 | 0.01 | -0.08 | 0.13 | Upgrade
|
| Earnings From Continuing Operations | 18.06 | 0.85 | 0.1 | -0.6 | -20.27 | -37.64 | Upgrade
|
| Net Income | 18.06 | 0.85 | 0.1 | -0.6 | -20.27 | -37.64 | Upgrade
|
| Net Income to Common | 18.06 | 0.85 | 0.1 | -0.6 | -20.27 | -37.64 | Upgrade
|
| Net Income Growth | 802.30% | 711.76% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 15 | 9 | 10 | 8 | 8 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 9 | 10 | 8 | 8 | 8 | Upgrade
|
| Shares Change (YoY) | 63.39% | -9.80% | 28.54% | - | - | - | Upgrade
|
| EPS (Basic) | 1.20 | 0.09 | 0.01 | -0.07 | -2.50 | -4.65 | Upgrade
|
| EPS (Diluted) | 1.20 | 0.09 | 0.01 | -0.07 | -2.50 | -4.65 | Upgrade
|
| EPS Growth | 458.69% | 800.00% | - | - | - | - | Upgrade
|
| Free Cash Flow | - | -137.91 | -3.43 | -24.1 | -2.12 | 15.63 | Upgrade
|
| Free Cash Flow Per Share | - | -14.69 | -0.33 | -2.98 | -0.26 | 1.93 | Upgrade
|
| Gross Margin | 3.04% | 3.73% | 15.14% | 27.99% | 6.94% | 10.69% | Upgrade
|
| Operating Margin | 1.86% | 0.41% | 0.85% | -3.04% | -5.41% | -38.19% | Upgrade
|
| Profit Margin | 1.41% | 0.27% | 0.23% | -3.12% | -22.74% | -39.27% | Upgrade
|
| Free Cash Flow Margin | - | -44.87% | -7.58% | -125.49% | -2.38% | 16.31% | Upgrade
|
| EBITDA | 24.23 | 1.65 | 0.77 | -0.02 | -4.02 | -34.52 | Upgrade
|
| EBITDA Margin | 1.89% | 0.53% | 1.69% | -0.12% | -4.51% | -36.02% | Upgrade
|
| D&A For EBITDA | 0.38 | 0.38 | 0.38 | 0.56 | 0.8 | 2.09 | Upgrade
|
| EBIT | 23.85 | 1.27 | 0.38 | -0.58 | -4.82 | -36.61 | Upgrade
|
| EBIT Margin | 1.86% | 0.41% | 0.85% | -3.04% | -5.41% | -38.19% | Upgrade
|
| Effective Tax Rate | 24.20% | 31.48% | 51.02% | - | - | - | Upgrade
|
| Revenue as Reported | 1,280 | 307.34 | 45.31 | 19.2 | 91.63 | 95.86 | Upgrade
|
| Advertising Expenses | - | 0.16 | 0.22 | 0.27 | 0.38 | 0.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.